Update on Nitrosamines – EMA/CMDh Publishes Revised Version of Q&A Document for MAHs Update on Nitrosamines The European Medicines Agency (EMA) and the Co-ordination group for Mutual recognition and Decentralised procedures – human... Update on Nitrosamines – EMA/CMDh Publishes Revised Version of Q&A Document for MAHs
MHRA Board Meeting – 19 April 2022 MHRA (Medicines and Healthcare products Regulatory Agency) Board Meeting – 19 April 2022 The MHRA Board will meet in public... MHRA Board Meeting – 19 April 2022
MHRA Request for Scientific Advice Contact Email Updated MHRA Request for Scientific Advice Contact Email Updated The MHRA has updated the request for scientific advice contact email address... MHRA Request for Scientific Advice Contact Email Updated
EMA – Report Published from 7th Industry Stakeholder Platform on R&D Support EMA – Report Published from 7th Industry Stakeholder Platform on R&D Support EMA has published the highlight report from the... EMA – Report Published from 7th Industry Stakeholder Platform on R&D Support
One Substance One Assessment – European Commission Consultation One Substance One Assessment – European Commission Consultation The European Commission has launched a call for evidence... One Substance One Assessment – European Commission Consultation
MHRA Webinar Recording – Medicines Supply for Northern Ireland MHRA Webinar Recording – Medicines Supply for Northern Ireland On Wednesday 2 February and Thursday 3 February 2022 the MHRA... MHRA Webinar Recording – Medicines Supply for Northern Ireland
MHRA 2021 Annual Report: Delivering High Standards in Medicines Advertising Regulation Published MHRA Publishes 2021 Annual Report ‘Delivering High Standards in Medicines Advertising Regulation’ Since 2006, the MHRA has published an annual... MHRA 2021 Annual Report: Delivering High Standards in Medicines Advertising Regulation Published
EMA HMPC – Public Consultation on Revised Concept of the GACP for Starting Materials of Herbal Origin EMA HMPC – Public Consultation on Revised Concept of the GACP for Starting Materials of Herbal Origin The Guideline on... EMA HMPC – Public Consultation on Revised Concept of the GACP for Starting Materials of Herbal Origin
EMA HMPC Launches Calls for Submission of Scientific Data EMA HMPC Calls for Submission of Scientific Data The European Medicines Agency’s (EMA) Committee on Herbal Medicinal Products (HMPC) has... EMA HMPC Launches Calls for Submission of Scientific Data
MHRA Updates Guidance on the Submission of Nitrosamine Risk Evaluation Update on MHRA’s submission of nitrosamine risk evaluation guidance, step 2 links updated In accordance with the... MHRA Updates Guidance on the Submission of Nitrosamine Risk Evaluation
MHRA Publishes Marketing Authorisations Granted in February 2022 MHRA’s list of marketing authorisations granted in February 2022 MHRA granted six OTC licences in February 2022. Details of these... MHRA Publishes Marketing Authorisations Granted in February 2022
EMA System Demo: DADI and PMS EMA System Demo: DADI and PMS On 15 March 2022 EMA is hosting a system demo on the Digital Application... EMA System Demo: DADI and PMS
